What is the drug for?

ERLEADA is a drug for the treatment of prostate cancer that has not spread to other parts of the body (non-metastatic) and no longer responds to a medical or surgical treatment that lowers testosterone (castration-resistant).

How is this drug used?

ERLEADA is a tablet. Four tablets (total of 240 mg) are taken once daily with or without food.

What are the benefits of this drug?

In the trial, ERLEADA increased the patients’ survival during which there was no spreading of the cancer (called metastasis-free survival). The median metastasis-free survival for patients taking ERLEADA was 40.5 months compared to 16.2 months for patients taking a placebo.